News | November 05, 2010

UIC Awarded $12 Million to Study Root Causes of Heart Failure

November 5, 2010 – The National Heart, Lung, and Blood Institute has awarded the University of Illinois at Chicago (UIC) more than $12 million to investigate the acquired and familial causes of heart failure. The goal is to identify markers for diagnosis and targets for cures.

The funding will support an ongoing program-project grant led by R. John Solaro, head of physiology and biophysics at UIC. Solaro’s program links the expertise of several UIC researchers together. Over the program’s 10-year life, dozens of papers have been published in top journals.

"We’re looking at the overarching problem of the maladaptive changes the heart undergoes that lead into a vicious cycle of failure," says Solaro.

His collaborators are Brenda Russell, professor in physiology and biophysics; E. Douglas Lewandowski, professor in physiology and biophysics; and Pieter de Tombe, chair of physiology at Loyola University, Chicago.

Projects led by Solaro and de Tombe investigate energy consumption by the molecular motors of the cardiac muscle, called sarcomeres, which generate the pressure to pump blood through the arteries. Pilot studies have identified possible therapies for common familial cardiac disorders for which there is presently no cure.

Russell addresses the mechanisms for growth of the heart-muscle cells and the assembly of the sarcomeres during growth.

Lewandowski focuses on the metabolic pathways that supply energy to the molecular motors and on the coordination of energy supply and demand. Cellular metabolism is important, he said, because scientists think "the interplay between protein function and expression in the heart, and metabolic processes in the cell, can either make or break the contractile function of the heart."

For more information: www.uic.edu


Related Content

News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
Subscribe Now